Elsevier

The Lancet

Volume 339, Issue 8793, 7 March 1992, Pages 572-575
The Lancet

ORIGINAL ARTICLES
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

https://doi.org/10.1016/0140-6736(92)90865-ZGet rights and content

Abstract

Nitric oxide (NO), synthesised from L-arginine, contributes to the regulation of blood pressure and to host defence. We describe in-vitro and in-vivo evidence that NO synthesis can be inhibited by an endogenous compound, NG,NG-dimethylarginine (asymmetrical dimethylarginine, ADMA). In man, this inhibitor is found in plasma and more than 10 mg is excreted in urine over 24 h. However, in patients with end-stage chronic renal failure, who have little or no urine output, elimination is blocked and circulating concentrations of the inhibitor rise sufficiently to inhibit NO synthesis. Accumulation of endogenous ADMA, leading to impaired NO synthesis, might contribute to the hypertension and immune dysfunction associated with chronic renal failure.

References (29)

  • S. Moncada et al.

    Nitric oxide: physiology, pathophysiology, and pharmacology

    Pharmacol Rev

    (1991)
  • Rmj Palmer et al.

    Vascular endothelial cells synthesize nitric oxide from L-arginine

    Nature

    (1988)
  • Jb Hibbs et al.

    L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells

    J Immunol

    (1987)
  • Rmj Palmer et al.

    Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

    Nature

    (1987)
  • Cited by (2013)

    View all citing articles on Scopus
    View full text